Skip to main content
VERU logo

VERU · Veru Inc.

Track VERU — free
$2.73 +0.03 (+1.11%) At close · Aug 14
Market Cap
$46.55M
Shares
17.05M

Veru Inc. Earnings Call Transcripts

Every quarterly earnings call for Veru Inc. (VERU) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Conference
Investor event
2026-08-12
Canaccord Genuity's 46th Annual Growth Investors Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-08-10
FY 2026 Q3 Earnings Conference Call
Confident tone Novo Nordisk clinical supply agreement GLP-1 weight loss plateau problem Commercial market opportunity and Medicare reimbursement
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-07-16
2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-05-13
Veru Inc. Q2 FY2026 Earnings Call
Confident tone Sarcopenic obesity in older patients Enobosarm Phase 2b Quality trial results GLP-1 receptor agonist limitations
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-02-26
Oppenheimer 36th Annual Healthcare Life Sciences Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-02-11
Veru Inc. Q4 FY2025 Earnings Call
Confident tone Novosarm obesity program Phase 2b PLATO study design Bone mineral density opportunity
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-09-30
Veru Inc. Q4 FY2025 Earnings Call
Confident tone Enobosarm Phase IIb trial results FDA regulatory guidance and pathway PLATEAU Phase IIb clinical trial design
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-08-12
Veru Inc. Q3 FY2025 Earnings Call
Confident tone Inovasaram Phase 2b QUALITY trial efficacy Physical function preservation (stair climb) Maintenance extension / weight regain prevention
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-05-08
Veru Inc. Q2 FY2025 Earnings Call
Confident tone Enobosarm + GLP-1 obesity program Physical function (Stair Climb) Body composition / tissue-selective weight loss
Revenue
$
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-02-13
Veru Inc. Q1 FY2025 Earnings Call
Confident tone Enobosarm Phase 2b QUALITY study results Phase 2b extension study Sabizabulin in atherosclerotic cardiovascular disease
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-08-08
Veru Inc. Q3 FY2024 Earnings Call
Revenue
$3.95M
▲ 18.3% YoY
Gross margin
33.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-05-08
Veru Inc. Q2 FY2024 Earnings Call
Positive tone Enobosarm for high-quality weight loss (with GLP-1) Phase IIb clinical trial design and endpoints Unmet need around muscle loss on GLP-1 drugs
Revenue
$4.14M
▼ 37.2% YoY
Diluted EPS
$-0.70
Gross margin
16.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-02-08
Veru Inc. Q1 FY2024 Earnings Call
Confident tone Enobosarm for high-quality weight loss with GLP-1 Phase IIb clinical trial design and milestone GLP-1 muscle loss unmet medical need
Revenue
$2.14M
▼ 14.6% YoY
Diluted EPS
$-0.80
Gross margin
53.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-08-10
Veru Inc. Q3 FY2023 Earnings Call
Revenue
$3.34M
▼ 65.2% YoY
Diluted EPS
$-1.40
Gross margin
36.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-05-11
Veru Inc. Q2 FY2023 Earnings Call
Revenue
$6.59M
▼ 49.4% YoY
Diluted EPS
$-4.20
Gross margin
62.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-02-09
Veru Inc. Q1 FY2023 Earnings Call
Revenue
$2.51M
▼ 82.3% YoY
Diluted EPS
$-4.80
Gross margin
28.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-05
Veru Inc. Q4 FY2022 Earnings Call
Revenue
$2.59M*
▼ 83.5% YoY
Gross margin
19.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-08-11
Veru Inc. Q3 FY2022 Earnings Call
Revenue
$9.60M
▼ 45.6% YoY
Diluted EPS
$-2.80
Gross margin
73.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-05-12
Veru Inc. Q2 FY2022 Earnings Call
Revenue
$13.03M
▼ 2.3% YoY
Diluted EPS
$-1.80
Gross margin
85.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-02-09
Veru Inc. Q1 FY2022 Earnings Call
Revenue
$14.14M
▼ 3.3% YoY
Diluted EPS
$-0.80
▼ 134.8% YoY
Gross margin
83.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-02
Veru Inc. Q4 FY2021 Earnings Call
Revenue
$15.65M*
▲ 33.2% YoY
Gross margin
78.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-08-12
Veru Inc. Q3 FY2021 Earnings Call
Revenue
$17.66M
▲ 71.1% YoY
Diluted EPS
$-0.30
Gross margin
78.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-05-12
Veru Inc. Q2 FY2021 Earnings Call
Revenue
$13.34M
▲ 34.2% YoY
Diluted EPS
$-0.40
Gross margin
81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-02-10
Veru Inc. Q1 FY2021 Earnings Call
Revenue
$14.62M
▲ 38.2% YoY
Diluted EPS
$2.30
Gross margin
74.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-09
Veru Inc. Q4 FY2020 Earnings Call
Revenue
$11.75M*
▲ 34.6% YoY
Gross margin
81.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-08-13
Veru Inc. Q3 FY2020 Earnings Call
Revenue
$10.32M
▲ 6.1% YoY
Diluted EPS
$-0.50
Gross margin
63.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-05-13
Veru Inc. Q2 FY2020 Earnings Call
Revenue
$9.94M
▲ 42.5% YoY
Diluted EPS
$-0.10
Gross margin
74.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-02-12
Veru Inc. Q1 FY2020 Earnings Call
Revenue
$10.58M
▲ 66% YoY
Diluted EPS
$-0.50
Gross margin
68.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–28 of 28 earnings calls
Key facts CIK 863894 CUSIP 92536C202 13F (30d) 61 filings 61 filers Visit website Investor relations